Hcw Biologics Stock Today
| HCWB Stock | USD 0.77 0.06 8.45% |
Performance7 of 100
| Odds Of DistressOver 72
|
HCW Biologics is trading at 0.77 as of the 25th of November 2024, a 8.45 percent increase since the beginning of the trading day. The stock's open price was 0.71. HCW Biologics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. Equity ratings for HCW Biologics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 6th of December 2022 and ending today, the 25th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of July 2021 | Category Healthcare | Classification Health Care |
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company was incorporated in 2018 and is headquartered in Miramar, Florida. The company has 37.82 M outstanding shares of which 8.09 K shares are currently shorted by private and institutional investors with about 0.28 trading days to cover. More on HCW Biologics
Moving against HCW Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
HCW Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsHCW Biologics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand HCW Biologics' financial leverage. It provides some insight into what part of HCW Biologics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
HCW Biologics (HCWB) is traded on NASDAQ Exchange in USA. It is located in 2929 North Commerce Parkway, Miramar, FL, United States, 33025 and employs 45 people. HCW Biologics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.95 M. HCW Biologics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 37.82 M outstanding shares of which 8.09 K shares are currently shorted by private and institutional investors with about 0.28 trading days to cover.
HCW Biologics currently holds about 32.41 M in cash with (22.51 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check HCW Biologics Probability Of Bankruptcy
Ownership AllocationHCW Biologics has a total of 37.82 Million outstanding shares. HCW Biologics secures noticeable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Check HCW Ownership Details
HCW Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2024-06-30 | 21.4 K | |
| Northern Trust Corp | 2024-09-30 | 10.2 K | |
| Tower Research Capital Llc | 2024-06-30 | 6.2 K | |
| Ubs Group Ag | 2024-06-30 | 4.3 K | |
| Royal Bank Of Canada | 2024-06-30 | 407 | |
| Bank Of America Corp | 2024-06-30 | 156 | |
| Wells Fargo & Co | 2024-06-30 | 0.0 | |
| Citadel Advisors Llc | 2024-09-30 | 0.0 | |
| Jpmorgan Chase & Co | 2024-06-30 | 0.0 | |
| Honkamp Krueger Financial Services Inc | 2024-09-30 | 279.5 K | |
| Geode Capital Management, Llc | 2024-09-30 | 183.3 K |
HCW Biologics Historical Income Statement
HCW Stock Against Markets
HCW Biologics Corporate Management
| Hing Wong | CEO, Founder | Profile | |
| Lee Flowers | Senior Development | Profile | |
| Peter Rhode | Chief Operations | Profile | |
| Nicole Esq | Vice Affairs | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in HCW Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For information on how to trade HCW Stock refer to our How to Trade HCW Stock guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of HCW Biologics. If investors know HCW will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about HCW Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share 0.107 | Quarterly Revenue Growth (0.01) | Return On Assets (0.70) | Return On Equity (3.44) |
The market value of HCW Biologics is measured differently than its book value, which is the value of HCW that is recorded on the company's balance sheet. Investors also form their own opinion of HCW Biologics' value that differs from its market value or its book value, called intrinsic value, which is HCW Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because HCW Biologics' market value can be influenced by many factors that don't directly affect HCW Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between HCW Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if HCW Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, HCW Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.